PeDRA

Pediatric Dermatology Research Alliance

Archive

PeDRA Session at SID

By

Recorded live on Wednesday, May 5, 2021. Hosted by Carrie Coughlin, MD from Washington University School of Medicine and Amy Paller, MD, MS from Northwestern University, this session will featured keynote speaker Eli Sprecher, MD, PhD from Tel Aviv Sourasky Medical Center and presentations from five selected abstracts. Follow the link below to watch the presentations.

PeDRA Session at the 2021 Society for Investigative Dermatology Virtual Meeting
Recorded Wednesday, May 5, 2021

Hosts: Carrie Coughlin, MD and Amy Paller MS, MD
Keynote Speaker: Eli Sprecher, MD, PhD

watch now
View agenda

Carrie Couglin, MD

Dr. Coughlin is the Director of the Section of Pediatric Dermatology and Assistant Professor of Dermatology at Washington University School of Medicine in St. Louis and St. Louis Children’s Hospital. Her practice is general pediatric dermatology, but she specializes in treating patients with pigmented skin lesions and immunosuppressed patients. She directs the Pediatric Melanoma and Nevus Clinic, part of Siteman Kids at St. Louis Children’s Hospital. She also holds a joint clinic with pediatric neuro-oncology caring for children with skin eruptions due to cancer therapies. She is Chair of the Skin Tumors and Reactions to Cancer therapies research group and the Outcomes Committee for the Pediatric Dermatology Research Alliance. She is the Treasurer for the International immunosuppression and Transplant Skin Cancer Collaborative. She enjoys leading an Art and Medicine class for first year medical students. 

    Eli Sprecher, MD, PhD

    Dr. Sprecher chairs the Division of Dermatology and serves as Deputy Director for Research and Development at the Tel Aviv Sourasky Medical Center. He is Frederick Reiss Professor of Dermatology at the Sackler Medical School, Tel Aviv University. He received an MD degree from the Hebrew University, a PhD degree in molecular virology from the Hebrew University and an MBA degree from Tel Aviv University. He specialized in dermatology at the Rambam Medical Center, Haifa and spent a post-doctoral fellowship in Human Genetics at the Thomas Jefferson University, Philadelphia. He served as Deputy Director for Academic Affairs at the Rappaport Institute for Research at the Technion-Israel Institute of Technology and founded as well as directed the Center for Translational Genetics at the same institution. He has co-authored over 300 scientific publications, has mentored over 50 students and has received numerous national and international prizes and honors. His research focuses on the genetic basis of skin diseases. His group aims at understanding the molecular genetics of both simple and complex traits, deciphering their pathogenesis and then attempting at translating this new knowledge into innovative therapeutic tools.

      Amy Paller, MS, MD

      Dr. Paller is the Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center (SBDRC) at Northwestern. She served as Chief of Pediatric Dermatology at Northwestern’s Children’s Hospital until she became Chair of Dermatology at Northwestern in 2004. An author of more than 500 peer-reviewed publications, Dr. Paller has also edited several major textbooks in dermatology, among them Hurwitz’s Clinical Pediatric Dermatology (now 6th edition) and Fitzpatrick’s Dermatology in General Medicine. She is an NIH-funded investigator in both her laboratory-based and clinical research. She has directed the Pediatric Dermatology Clinical Trials Unit at Northwestern/ Lurie Children’s for the past 30 years and has been the lead investigator on several landmark trials in pediatric skin disease, particularly related to atopic dermatitis (AD), psoriasis, and genodermatoses. Her laboratory focuses on skin innervation in inflammatory diseases, wound healing, and topically delivered gene regulation through nanotherapy. She has defined skin and blood biomarkers for children with AD and ichthyoses towards pathogenesis-directed therapy and has developed new patient-related outcomes scales for itch and stigma in children. Dr. Paller was the inaugural President of the International Eczema Council and inaugural co-President of the Pediatric Dermatology Research Alliance. She has been President of the Society for Investigative Dermatology, Society for Pediatric Dermatology, and the Women’s Dermatologic Society. She is currently President of the International Society for Pediatric Dermatology. She has served on Council and the Board of Scientific Councilors for NIH/NIAMS, and on numerous boards for dermatology patient advocacy organizations. She has received several honors for her scholarship, leadership and mentorship, among them election to the American Association of Physicians and the American Dermatological Association, and awarding of the Stephen Rothman Award from the Society for Investigative Dermatology, Mentor of the Year, Rose Hirschler, and the Wilma Bergfeld, MD Visionary & Leadership awards from the Women’s Dermatological Society, the Clarence S. Livingood, MD Memorial Award from the AAD, the Founder’s Award from the Chicago Dermatological Society, the Tanioku Kihei Memorial Award from the Japanese Society for Investigative Dermatologist, and the inaugural Paula Stern Outstanding Women in Science and Medicine Award from Northwestern.

        Webinar: Using Social Media to Advance Your Career

        By

        Hosted on February 10, 2021. Learn how to promote your science via social media channels. Featured presenters Dr. John Harris, and Dr. Daniel Sugai shared their experiences with social media and answered questions.

        This program is run in partnership with the Society for Pediatric Dermatology Junior Faculty/Fellows Committee.

        Using Social Media to Advance Your Career with Live Q&A
        Wednesday, February 10, 2021 at 5:30PM PST / 8:30PM EST

        This event is for PeDRA and SPD members only – pre-registration is required.

        Hosts: Jiade Yu, MD and Lisa Arkin, MD

        Speakers
        John Harris, MD, PhD
        Daniel Sugai, MD

        Watch now

        Speakers

        Daniel Sugai, MD

        Dr. Daniel Sugai was born and raised on the Hawaiian island of Oahu where he studied biology and art in college at the University of Hawaii. He then went on and got his M.D. from the University of Hawaii and was Class President and President of his school’s AOA Honor Society. He completed his dermatology training in the Harvard Combined Dermatology Residency Program where he trained at Mass General Hospital/BWH/Beth Israel Deaconess Medical Center/Boston Children’s Hospital. Upon graduating from residency and passing his board certification examination, he moved to Seattle, WA and practices medical, cosmetic and surgical dermatology- seeing pediatrics and adults. He received multiple “Top Doctor” accolades including Seattle Met Magazine Top Doctor 2020. At the start of the pandemic in March/April 2020, Dr. Sugai started a YouTube channel, Instagram and TikTok to help disseminate credible science-backed skin education to the masses. It has become a “second job” and a passion of his and he enjoys connecting with people from all around the globe. 

          John Harris, MD, PhD

          Dr. Harris is the Chair of Dermatology, Founding Director of the Vitiligo Clinic and Research Center, and Founding Director of the Autoimmune Therapeutics Institute at UMass Medical School in Worcester, Massachusetts. He is a dermatologist and physician-scientist, caring for patients in a vitiligo specialty clinic and running a large research laboratory focused on understanding disease pathogenesis and developing new treatments. His group integrates basic, translational, and clinical research strategies to accomplish this. As a result, early clinical trials in vitiligo have shown success, and more are being developed. Finally, Dr. Harris founded Villaris Therapeutics, whose entire focus is to develop an effective, long-lasting treatment for vitiligo.

            Webinar: Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session

            By

            Hosted on January 11, 2021. PeDRA President-Elect Anna Bruckner, MD, MSCS gave a presentation on basic biology underlying EB and recent advances in EB clinical research. Webinar sponsored by Amryt Research Ltd.

            Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session, Sponsored by Amryt Research Ltd.
            Monday, January 11, 2021, 5:30 PM PST / 8:30 PM EST

            Speaker: Anna Bruckner, MD, MSCS

            WATCH NOW

            Speaker

            Anna Bruckner, MD, MSCS

            Dr. Bruckner is Associate Professor of Dermatology and Pediatrics and at the University of Colorado School of Medicine and Director of Pediatric Dermatology at Children’s Hospital Colorado. She attended Northwestern University as part of the Honors Program in Medical Education, earning her MD in 1997. She completed residencies pediatrics and dermatology at the University of Colorado followed by a fellowship in pediatric dermatology at the University of California San Francisco. She maintains board-certification in dermatology and pediatric dermatology.

            Dr. Bruckner is passionate about improving outcomes and quality of life for children with skin disorders through patient care, research, education and advocacy. Her academic interests include genetic skin disorders – particularly epidermolysis bullosa (EB), vascular anomalies, atopic dermatitis, and complex patients. She is the principal investigator for the Epidermolysis Bullosa Clinical Research Consortium, a network of North American EB care centers collaborating in clinic research aimed at improving the care and outcomes for patients with EB.

            Dr. Bruckner is a founding member of the Pediatric Dermatology Research Alliance (PeDRA) and served on PeDRA’s Executive Committee until 2016. She is now the 2022 President-Elect.

              PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at info@pedraresearch.org with any questions or concerns. This webinar is being hosted by PeDRA and sponsored by Amryt Research Ltd.
              Date of preparation: December 2020. VV-MED-00552

              Webinar: EB-101 Clinical Development Update and Q&A Session

              By

              Hosted on November 12, 2020 in partnership with Abeona Therapeutics, this webinar presented cutting edge clinical development updates towards the treatment of epidermolysis bullosa. The webinar featured presentations from Jean Tang, MD, PhD (Professor of Dermatology, Stanford University Medical Center and Principal Investigator, EB-101 pivotal Phase 3 VIITAL study) and Michael Amoroso (Chief Commercial Officer, Abeona) and moderated discussion.

              EB-101 Clinical Development Update and Q&A Session, sponsored by Abeona Therapeutics
              Thursday, November 12, 2020 8:00 AM PST / 11:00 AM EST

              Speakers: Jean Tang, MD, PhD and Michael Amoroso

              watch now

              Speakers

              Jean Tang, MD, PhD

              Professor of Dermatology, Stanford University Medical Center AND Principal Investigator, EB-101 pivotal Phase 3 VIITAL study

              Dr. Tang’s research focuses on genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. She studies new ways to treat and prevent NSMC and melanoma. Dr. Tang has led or co-led the conduct and completion of 6 investigator initiated clinical trials in BCC and EB. She received her MD/PhD from Stanford (Biophysics), completed her dermatology residency at Stanford, and then went to UCSF for a 3 year post-doc in mouse genetics, while simultaneously pursuing formal coursework in biostatistics, epidemiology, and clinical trial design in the KL2 CTSI program.

                Michael Amoroso, MBA

                Chief Commercial Officer, Abeona

                Michael Amoroso joined Abeona as Senior Vice President and Chief Commercial Officer in July 2020, bringing over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries with a focus on cell and gene therapies, and a proven track record of launching innovative drugs for rare diseases.

                Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi.

                Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.

                  This webinar is being hosted by PeDRA and sponsored by Abeona Therapeutics. PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at info@pedraresearch.org with any questions or concerns.

                  Series: Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children

                  By

                  Moderate-to-severe atopic dermatitis is associated with negative impacts on quality of life and health outcomes in all age groups, with the impact on children and families being uniquely severe. However, the rapid pace of drug development and uncertainty around novel medications may impact the shared decision-making process and lead to suboptimal treatment of many children. Thus, educating pediatric dermatologists and allergists is critical to positively affect treatment decisions and improve long-term outcomes. In addition, engaging experts in pediatric dermatology and allergy to consider what are the most important research issues in atopic dermatitis is important to direct future efforts. To address this need and help fill the gap left by canceled conferences in 2020, PeDRA is conducting a six-part educational series Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children.      

                  Being hosted by distinguished faculty in pediatric dermatology and allergy/immunology, this non-CME program will include a total of six parts, including two webinars, two podcasts, and two virtual meetings/townhalls. 

                  Part 1: PEDIATRIC ATOPIC DERMATITIS – New and Emerging Systemic Therapies: An Overview
                  RECORDED LIVE: Tuesday, October 6, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT

                  Chair: Lawrence Eichenfield, MD
                  Speakers: Megha Tollefson, MD and Bob Geng, MD
                  Panel: Wynnis Tom, MD and Dawn Davis, MD

                  View Full Agenda

                  5:15 – 5:20 – Introduction
                  5:20 – 5:37 – Biologics – Overview and translation to practice
                  5:37 – 5:49 – JAK-inhibitors
                  5:49 – 6:01 – Mechanisms of action and allergy perspectives
                  6:01 – 6:15 – Moderated discussion with audience

                  Watch NOW

                  Part 2: PEDIATRIC ATOPIC DERMATITIS – Algorithms of the Future
                  RECORDED LIVE: Tuesday, October 13, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT

                  Chair: Lawrence Eichenfield, MD
                  Speakers: Dawn Davis, MD and Wynnis Tom, MD
                  Panel: Megha Tollefson, MD and Bob Geng, MD

                  View Full Agenda

                  5:15 – 5:20 – Introduction
                  5:20 – 5:32 – New topicals for moderate to severe disease
                  5:32 – 5:42 – New and traditional systemics: where do they fit?
                  5:42 – 6:00 – Considerations when selecting appropriate therapy for the appropriate patient
                  6:00 – 6:15 – Interactive discussion on “hot” research issues in moderate to severe atopic dermatitis for pediatric dermatologists and allergists

                  Watch now

                  Part 3: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
                  AVAILABLE NOW

                  Host: Lawrence Eichenfield, MD
                  Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
                  Guests

                  LISTEN NOW:

                  Subscribe to PeDRA Podcasts

                  Part 4: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
                  Tuesday, December 8, 2020 5:15 – 6:15PM PST / 8:15 – 9:15PM EST

                  Host: Lawrence Eichenfield, MD
                  Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
                  Special Guests: Emma Guttman-Yassky, MD, PhD and Eric Simpson, MD

                  LISTEN NOW:

                  Subscribe to PeDRA Podcasts

                  Part 5: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
                  AVAILABLE NOW

                  Host: Dawn Davis, MD
                  Special Guests: Charlene Miciano and Sarah Pry

                  LISTEN NOW:

                  Subscribe to PeDRA Podcasts

                  Part 6: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
                  Tuesday, January 5, 2021, 5:15 – 6:15PM PST / 8:15 – 9:15PM EST

                  An open discussion with faculty and patient advocates in follow-up to the second podcast. Bring your questions or just listen in.

                  Host: Dawn Davis, MD
                  Guests: Lawrence Eichenfield, MD, Bob Geng, MD, and Wynnis Tom, MD
                  Special Guests: Korey Capozza, MPH from Global Parents for Eczema Research and Wendy Smith Begolka, MBS from the National Eczema Association

                  LISTEN NOW:

                  Subscribe to PeDRA Podcast

                  FACULTY

                  Lawrence Eichenfield, MD

                  Chair

                  Professor of Dermatology and Pediatrics
                  Chief, Pediatric and Adolescent Dermatology
                  Vice Chair, Department of Dermatology
                  University of California, San Diego and Rady Children’s Hospital, San Diego

                    Bob Geng, MD

                    Assistant Professor of Medicine and Pediatrics
                    Divisions of Adult and Pediatric Allergy & Immunology
                    Co-Director of the Allergy Asthma Foundation of America sponsored UCSD Pediatric Severe Asthma Program
                    Allergy/Immunology Director of the Multidisciplinary Atopic Dermatitis Program
                    University of California, San Diego and Rady Children’s Hospital, San Diego

                      Dawn Davis, MD

                      Professor of Dermatology and Pediatrics
                      Division Chair, Clinical Dermatology
                      Director, Section of Pediatric Dermatology
                      Mayo Clinic Rochester

                        Megha Tollefson, MD

                        Associate Professor of Dermatology and Pediatrics
                        Consultant, Dermatology
                        Consultant, Pediatric and Adolescent Medicine
                        Mayo Clinic Rochester

                          Wynnis Tom, MD

                          Clinical Professor of Dermatology and Pediatrics
                          Fellowship Program Director
                          Pediatric & Adolescent Dermatology
                          University of California, San Diego and Rady Children’s Hospital, San Diego

                            SPECIAL GUESTS

                            Emma Guttman-Yassky, MD, PhD

                            Vice Chair for Research
                            Incoming System Chair of the Kimberly and Eric J. Waldman Department of Dermatology
                            Icahn School of Medicine at Mount Sinai

                              Charlene Miciano

                              Charlene is a college student from San Diego majoring in bioinformatics. Her experience with eczema growing up influenced her to become an ambassador for the National Eczema Association. When she’s not coding, she enjoys music in many forms, whether it be playing piano or ukulele, doing karaoke, or going to concerts.

                                Korey Capozza, MPH

                                Korey is the founder and executive director of Global Parents for Eczema Research and the mother of a child with moderate to severe eczema. Her professional background is in public health, collaborative leadership, and patient-centered research.

                                  Eric Simpson, MD

                                  Professor of Dermatology
                                  Oregon Health and Science University

                                    Sarah Pry

                                    Sarah is a mother of 2, Aiden age 12 and Bayle age 8. Aiden has severe eczema. Sarah works full time as an insurance agent in TN and in what spare time she has as a mom, she plays with her kids. She also loves to advocate and learn from the experts by volunteering or helping anyway that she can.

                                      Wendy Smith Begolka, MBS

                                      Ms. Smith Begolka is the VP for Scientific and Clinical Affairs for the National Eczema Association (NEA) where she guides the evolution and growth of NEA’s patient-centric research and clinical care efforts across the organization and with diverse stakeholders. Prior to joining NEA in 2018, she conducted biomedical laboratory research investigating immunological pathways of autoimmune disease at Northwestern University, and for over a decade, led the development of American Academy of Dermatology clinical guidelines and the application of science to the intersecting areas of quality, education, and advocacy. Her 25+ year scientific career has focused on advancing research, the use of scientific discovery and findings to support improved therapeutic options and clinical care, and the translation of research data for educational, quality, advocacy, and policy initiatives.

                                        Special thanks to Pfizer Inc. for their support of this independent medical education program.  PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.

                                        Town Hall: Impacts of COVID-19 on Children with Dermatological Disease

                                        By

                                        In collaboration with PeDRA, GlobalSkin hosted a virtual townhall on June 30, 2020 with Dr. Kelly Cordoro and Dr. Amy Paller to discuss the impact of COVID-19 on children and action being taken by the pediatric dermatology researchers.

                                        GlobalSkin, also known as the International Alliance for Dermatology Patient Organizations (IADPO), is a nonprofit organization supporting more than 160 patient associations across more than 50 countries. They seek to improve the lives of patients with all skin disease through advocacy, education, networking, and research. To learn more, visit the GlobalSkin website.

                                        Webinar: From the NICU to Eczema and the Value of Research Funding

                                        By

                                        Tune in to hear Jennifer Schoch, MD from University of Florida discuss her research in the microbiome and eczema, and learn about the value of PeDRA funding.

                                        Jennifer Schoch, MD

                                        Jennifer Schoch, MD is Pediatric Dermatologist and Assistant Professor of Dermatology at the University of Florida. She is the recipient of a PeDRA Pilot Grant (2018), SPD/PeDRA Weston Career Development award (2019-20), PeDRA Shark Tank Award (2020-21) and an NIH KL2 Award (2020-22).